A5073728088- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- DNA Repair Mechanisms
- Cancer-related Molecular Pathways
- Brain Metastases and Treatment
- Cancer Risks and Factors
- Estrogen and related hormone effects
- Genetic factors in colorectal cancer
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer-related cognitive impairment studies
- Cancer survivorship and care
- Chronic Lymphocytic Leukemia Research
- Breast Lesions and Carcinomas
- Lung Cancer Research Studies
- Medical Imaging Techniques and Applications
- Angiogenesis and VEGF in Cancer
- Global Cancer Incidence and Screening
- Childhood Cancer Survivors' Quality of Life
Dana-Farber Cancer Institute
2016-2025
Boston University
2013-2025
Harvard University
2012-2024
Dana-Farber Brigham Cancer Center
2012-2024
Dana-Farber/Harvard Cancer Center
2024
CancerCare
2024
Brigham and Women's Hospital
2007-2022
GEICAM – Spanish Breast Cancer Group
2021
Memorial Sloan Kettering Cancer Center
2021
The University of Texas MD Anderson Cancer Center
2012-2021
Purpose Cardiac dysfunction is a serious adverse effect of certain cancer-directed therapies that can interfere with the efficacy treatment, decrease quality life, or impact actual survival patient cancer. The purpose this effort was to develop recommendations for prevention and monitoring cardiac in survivors adult-onset cancers. Methods Recommendations were developed by an expert panel multidisciplinary representation using systematic review (1996 2016) meta-analyses, randomized clinical...
Previous research evaluating adherence to tamoxifen therapy among women with early-stage breast cancer has revealed estimates ranging from 25% 96%. No previous studies have focused on adjuvant aromatase inhibitors.We used longitudinal claims data three large commercial health programs estimate anastrozole cancer. Adherence was defined as the proportion of days that patients had medication available over observation period (ie, covered); fewer than 80% covered were nonadherent.More 12,000 in...
Epidermal growth factor receptor (EGFR) is a targetable frequently overexpressed in basal-like breast cancer, which comprises most triple-negative cancers (TNBCs), the only subtype without established targeted therapy.In this randomized phase II trial, patients with metastatic TNBC received anti-EGFR antibody cetuximab (400 mg/m(2) load then 250 per week intravenously [IV]) alone, carboplatin (area under curve of 2, once IV) added after progression or as concomitant therapy from beginning....
The identification of patients with metastatic triple-negative breast cancer (mTNBC) who are expected to benefit from platinum-based chemotherapy is interest. We conducted a single-arm phase II clinical trial single-agent platinum for mTNBC biomarker correlates.Patients received first- or second-line cisplatin (75 mg/m(2)) carboplatin (area under the concentration-time curve 6) by physician's choice once every 3 weeks. Coprimary end points were objective response rate (RR) and prediction...
To update recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage cancer.An updated literature search identified randomized clinical trials prospective-retrospective studies published from January 2016 October 2021. Outcomes interest included overall survival disease-free or recurrence-free survival. Expert Panel members used informal consensus develop evidence-based recommendations.The 24 informing the...
Purpose We compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line therapy for patients advanced breast cancer (BC) evaluate progression-free survival (PFS) versus paclitaxel. Patients and Methods Eligible were age ≥ 18 years chemotherapy-naive BC. randomly assigned 90 mg/m 2 (arm A), 150 B), 16 C), 3 of 4 weeks. Planned enrollment was 900 patients, which would give 88% power detect a hazard ratio 0.73. Results In all, 799 enrolled, 783 received...
Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, potential value of adding palbociclib to endocrine therapy hormone receptor-positive cancer has not been confirmed.
Abstract Purpose: Existing cell-free DNA (cfDNA) methods lack the sensitivity needed for detecting minimal residual disease (MRD) following therapy. We developed a test tracking hundreds of patient-specific mutations to detect MRD with 1,000-fold lower error rate than conventional sequencing. Experimental Design: compared our approach digital droplet PCR (ddPCR) in dilution series, then retrospectively identified two cohorts patients who had undergone prospective plasma sampling and clinical...
Patients with triple-negative breast cancer (TNBC) and residual invasive disease (RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for recurrence, which is reduced by adjuvant capecitabine. Preclinical models support the use platinum agents in TNBC basal subtype. The EA1131 trial hypothesized that disease-free survival (iDFS) would not be inferior but improved patients subtype treated compared
Abstract Background CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) have a well-established role the management of hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC). The benefit continuing CDK4/6i beyond progression different ET has not been confirmed. Preclinical data suggest synergy between and PD-L1 inhibition. PACE trial prospectively evaluates whether continuation CKD4/6i palbociclib on prior aromatase inhibitor (AI), change to fulvestrant,...
Cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6is) are an important component of treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC), but it is not known if patients might derive benefit from continuation CDK4/6i with endocrine therapy beyond initial tumor progression or the addition checkpoint inhibitor has value in this setting.
Adding CDK4/6 inhibitors (CDK4/6is) to endocrine therapy (ET) for HR+/HER2− early breast cancer (EBC) demonstrated statistically significant invasive disease-free survival (iDFS) benefits in monarchE (node positive, high risk, stage II/III) and NATALEE (select N0 all macroscopic N1, II/III). This study evaluated patient preferences EBC treatment attributes how these may translate CDK4/6i selection. A web-based discrete choice experiment survey was conducted among US-based adult women with...
Abstract Purpose: Because of inherent disease heterogeneity, targeted therapies have eluded triple-negative breast cancer (TNBC), and biomarkers predictive treatment response not yet been identified. This study was designed to determine whether the mTOR inhibitor everolimus with cisplatin paclitaxel would provide synergistic antitumor effects in TNBC. Methods: Patients stage II/III TNBC were enrolled a randomized phase II trial preoperative weekly cisplatin, daily or placebo for 12 weeks,...
Abstract Purpose: Preclinical data demonstrating androgen receptor (AR)–positive (AR+) triple-negative breast cancer (TNBC) cells are sensitive to AR antagonists, and PI3K inhibition catalyzed an investigator-initiated, multi-institutional phase Ib/II study TBCRC032. The trial investigated the safety efficacy of AR-antagonist enzalutamide alone or in combination with inhibitor taselisib patients metastatic AR+ (≥10%) cancer. Patients Methods: Phase Ib [estrogen positive (ER+) TNBC] received...
Genomic profiling of ER + /HER2 − breast tumors after short-term estrogen deprivation revealed alterations associated with intrinsic resistance and provided mechanistic insights.
Platinum compounds have activity in triple-negative breast cancer (TNBC) germline BRCA mutation carriers (BRCA carriers). Limited data exist for estrogen receptor (ER)-positive (+) among carriers. INFORM is a randomized, multicenter, phase II trial comparing pathologic complete response (pCR) rates (ypT0/is, N0) after neoadjuvant single-agent cisplatin (CDDP) versus doxorubicin-cyclophosphamide (AC) with stage I-III human epidermal growth factor 2 (HER2)-negative cancer. Secondary objectives...